Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with no Detectable Immunity

被引:33
作者
Guilbaud, Mickael [1 ]
Devaux, Marie [1 ]
Couzinie, Celia [1 ]
Le Duff, Johanne [1 ]
Toromanoff, Alice [1 ]
Vandamme, Celine [1 ]
Jaulin, Nicolas [1 ]
Gernoux, Gwladys [1 ]
Larcher, Thibaut [2 ]
Moullier, Philippe [1 ]
Le Guiner, Caroline [1 ]
Adjali, Oumeya [1 ]
机构
[1] Univ Nantes, Translat Gene Therapy Genet Dis, INSERM, UMR 1089, Nantes, France
[2] Oniris, PAnTher, INRA, UMR 703, Nantes, France
关键词
AAV; gene transfer; locoregional delivery; nonhuman primate; immunogenicity; long-term follow-up; MEDIATED GENE-TRANSFER; LIPOPROTEIN-LIPASE DEFICIENCY; FACTOR-IX EXPRESSION; LONG-TERM CORRECTION; HEMOPHILIA-B DOGS; T-CELL RESPONSES; AAV-FACTOR-IX; SKELETAL-MUSCLE; CANINE MODEL; VIRAL VECTORS;
D O I
10.1089/hum.2018.234
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Anti-transgene immune responses elicited after intramuscular (i.m.) delivery of recombinant adeno-associated virus (rAAV) have been shown to hamper long-term transgene expression in large-animal models of rAAV-mediated gene transfer. To overcome this hurdle, an alternative mode of delivery of rAAV vectors in nonhuman primate muscles has been described: the locoregional (LR) intravenous route of administration. Using this injection mode, persistent inducible transgene expression for at least 1 year under the control of the tetracycline-inducible Tet-On system was previously reported in cynomolgus monkeys, with no immunity against the rtTA transgene product. The present study shows the long-term follow-up of these animals. It is reported that LR delivery of a rAAV2/1 vector allows long-term inducible expression up to at least 5 years post gene transfer, with no any detectable host immune response against the transactivator rtTA, despite its immunogenicity following i.m. gene transfer. This study shows for the first time a long-term regulation of muscle gene expression using a Tet-On-inducible system in a large-animal model. Moreover, these findings further confirm that the rAAV LR delivery route is efficient and immunologically safe, allowing long-term skeletal muscle gene transfer.
引用
收藏
页码:802 / 813
页数:12
相关论文
共 65 条
[1]   Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness [J].
Acland, GM ;
Aguirre, GD ;
Bennett, J ;
Aleman, TS ;
Cideciyan, AV ;
Bennicelli, J ;
Dejneka, NS ;
Pearce-Kelling, SE ;
Maguire, AM ;
Palczewski, K ;
Hauswirth, WW ;
Jacobson, SG .
MOLECULAR THERAPY, 2005, 12 (06) :1072-1082
[2]  
[Anonymous], 2018, MED LETT DRUGS THER, V60, P53
[3]   Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B [J].
Arruda, Valder R. ;
Stedman, Hansell H. ;
Haurigot, Virginia ;
Buchlis, George ;
Baila, Stefano ;
Favaro, Patricia ;
Chen, Yifeng ;
Franck, Helen G. ;
Zhou, Shangzhen ;
Wright, J. Fraser ;
Couto, Linda B. ;
Jiang, Haiyan ;
Pierce, Glenn F. ;
Bellinger, Dwight A. ;
Mingozzi, Federico ;
Nichols, Timothy C. ;
High, Katherine A. .
BLOOD, 2010, 115 (23) :4678-4688
[4]   Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1 [J].
Arruda, VR ;
Schuettrumpf, J ;
Herzog, RW ;
Nichols, TC ;
Robinson, N ;
Lotfi, Y ;
Mingozzi, F ;
Xiao, WD ;
Couto, LB ;
High, KA .
BLOOD, 2004, 103 (01) :85-92
[5]   Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model [J].
Arruda, VR ;
Stedman, HH ;
Nichols, TC ;
Haskins, ME ;
Nicholson, M ;
Herzog, RW ;
Couto, LB ;
High, KA .
BLOOD, 2005, 105 (09) :3458-3464
[6]   Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals [J].
Asokan, A. ;
Johnson, J. S. ;
Li, C. ;
Samulski, R. J. .
GENE THERAPY, 2008, 15 (24) :1618-1622
[7]   Regulated and liver-specific tamarin alpha interferon gene delivery by a helper-dependent adenoviral vector [J].
Aurisicchio, L ;
De Tomassi, A ;
La Monica, N ;
Ciliberto, G ;
Traboni, C ;
Palombo, F .
JOURNAL OF VIROLOGY, 2005, 79 (11) :6772-6780
[8]   Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC [J].
Bankiewicz, Krystof S. ;
Forsayeth, John ;
Eberling, Jamie L. ;
Sanchez-Pernaute, Rosario ;
Pivirotto, Philip ;
Bringas, John ;
Herscovitch, Peter ;
Carson, Richard E. ;
Eckelman, William ;
Reutter, Bryan ;
Cunningham, Janet .
MOLECULAR THERAPY, 2006, 14 (04) :564-570
[9]   Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions [J].
Basner-Tschakarjan, Etiena ;
Mingozzi, Federico .
FRONTIERS IN IMMUNOLOGY, 2014, 5
[10]   Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial [J].
Bennett, Jean ;
Wellman, Jennifer ;
Marshall, Kathleen A. ;
McCague, Sarah ;
Ashtari, Manzar ;
DiStefano-Pappas, Julie ;
Elci, Okan U. ;
Chung, Daniel C. ;
Sun, Junwei ;
Wright, J. Fraser ;
Cross, Dominique R. ;
Aravand, Puya ;
Cyckowski, Laura L. ;
Bennicelli, Jeannette L. ;
Mingozzi, Federico ;
Auricchio, Alberto ;
Pierce, Eric A. ;
Ruggiero, Jason ;
Leroy, Bart P. ;
Simonelli, Francesca ;
High, Katherine A. ;
Maguire, Albert M. .
LANCET, 2016, 388 (10045) :661-672